Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 5/20 | 0.45 |
| ▸ | CCR2 | P41597 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014544 | 0.87 | MAPT (0.43) | PTGES2CCR2POLBTP53TDP1 | |
| SCHEMBL4017635 | 0.86 | CCR2 (0.42) | PTGES2CCR2POLBTP53TDP1 | |
| SCHEMBL4009012 | 0.86 | KMT2A (0.46) | PTGES2CCR2POLBTP53TDP1 | |
| SCHEMBL4008442 | 0.85 | MAP2K4 (0.48) | PTGES2MAPTMAP2K7MAP2K4 | |
| SCHEMBL4007219 | 0.83 | TP53 (0.43) | PTGES2CCR2POLBTP53TDP1 | |
| SCHEMBL4009500 | 0.82 | BRAF (0.45) | PTGES2POLBTP53TDP1KMT2A | |
| SCHEMBL4013522 | 0.81 | POLB (0.52) | POLBTP53TDP1KMT2ALMNA | |
| SCHEMBL4006558 | 0.79 | CDK7 (0.50) | POLBTDP1KMT2ALMNAMAPT | |
| SCHEMBL4009872 | 0.79 | CSNK2A1 (0.55) | POLBKMT2AGAA | |
| SCHEMBL1460532 | 0.79 | BRD4 (0.50) | KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| CN-100369899-C | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | CN | disclosed |
| CN-1642922-A | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2005-07-20 | — | — | CN | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | PTGES2 2520/4885CCR2 3475/4885POLB 1912/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | PTGES2 2435/4885CCR2 3578/4885POLB 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.